High plasma efavirenz concentration and CYP2B6 polymorphisms in Thai HIV-1 infections

Drug Metabolism and Pharmacokinetics

Volumn 28, Issue 5, 2013, Pages 391-397

  Sukasem, Chonlaphat ^a   Chamnanphon, Montri ^a   Koomdee, Napatrupron ^a   Puangpetch, Apichaya ^a   Santon, Siwalee ^a   Jantararoungtong, Thawinee ^a   Prommas, Santirat ^a   Chantratita, Wasun ^a   Manosuthi, Weerawat ^b  

^a MAHIDOL UNIVERSITY   (Thailand)

^b MINISTRY OF PUBLIC HEALTH   (Thailand)

Author keywords

CYP2B6; Drug level; Efavirenz; HIV 1; Pharmacogenetics; SNP

Indexed keywords

CYTOCHROME P450 2B6; EFAVIRENZ; LAMIVUDINE; TENOFOVIR;

ADULT; ALLELE; ARTICLE; BEDTIME DOSAGE; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; CYP2B6 GENE; DRUG BLOOD LEVEL; DRUG METABOLISM; FEMALE; GENE FREQUENCY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; REAL TIME POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; THAILAND;

ADULT; ARYL HYDROCARBON HYDROXYLASES; ASIAN CONTINENTAL ANCESTRY GROUP; BENZOXAZINES; HIV INFECTIONS; HUMANS; POLYMORPHISM, SINGLE NUCLEOTIDE; THAILAND;

EID: 84880504005     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.DMPK-12-RG-120     Document Type: Article

References (39)

1. Thompson, M. A., Aberg, J. A., Cahn, P., Montaner, J. S., Rizzardini, G., Telenti, A., Gatell, J. M., Gunthard, H. F., Hammer, S. M., Hirsch, M. S., Jacobsen, D. M., Reiss, P., Richman, D. D., Volberding, P. A., Yeni, P. and Schooley, R. T.: Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA, 304: 321-333 (2010).
2. Marzolini, C., Telenti, A., Decosterd, L. A., Greub, G., Biollaz, J. and Buclin, T.: Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS, 15: 71-75 (2001).
3. Haas, D. W., Ribaudo, H. J., Kim, R. B., Tierney, C., Wilkinson, G. R., Gulick, R. M., Clifford, D. B., Hulgan, T., Marzolini, C. and Acosta, E. P.: Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS, 18: 2391-2400 (2004).
4. Núñez, M., González, de R. D., Gallego, L., Jiménez-Nácher, I., González-Lahoz, J. and Soriano, V.: Higher efavirenz plasma levels correlate with development of insomnia. J. Acquir. Immune Defic. Syndr., 28: 399-400 (2001).
5. Rodriguez-Novoa, S., Barreiro, P., Rendón, A., Jiménez-Nacher, I., González-Lahoz, J. and Soriano, V.: Influence of 516G>T polymorphisms at the gene encoding the CYP450-2B6 isoenzyme on efavirenz plasma concentrations in HIV-infected subjects. Clin. Infect. Dis., 40: 1358-1361 (2005).
6. Cabrera, S. E., Santos, D., Valverde, M. P., Domínguez-Gil, A., González, F., Luna, G. and García, M. J.: Influence of the Cytochrome P450 2B6 Genotype on Population Pharmacokinetics of Efavirenz in Human Immunodeficiency Virus Patients. Antimicrob. Agents Chemother., 53: 2791-2798 (2009).
7. Sukasem, C., Cressey, T. R., Prapaithong, P., Tawon, Y., Pasomsub, E., Srichunrusami, C., Jantararoungtong, T., Lallement, M. and Chantratita, W.: Pharmacogenetic Markers of CYP2B6 Associated with Efavirenz Plasma Concentrations in HIV-1 infected Thai Adults. Br. J. Clin. Pharmacol., 74: 1005-1012 (2012).
8. Manosuthi, W., Sukasem, C., Lueangniyomkul, A., Mankatitham, W., Thongyen, S., Nilkamhang, S., Manosuthi, S. and Sungkanuparph, S.: Impact of Pharmacogenetic Markers of CYP2B6, Clinical Factors, and Drug-Drug Interaction on Efavirenz Concentrations in HIV/Tuberculosis Co-Infected Patients. Antimicrob. Agents Chemother., 57: 1019-1024 (2013).
9. Gounden, V., van Niekerk, C., Snyman, T. and George, J. A.: Presence of the CYP2B6 516G> T polymorphism, increased plasma Efavirenz concentrations and early neuropsychiatric side effects in South African HIV-infected patients. AIDS Res. Ther., 7: 32 (2010).
10. Ward, B. A., Gorski, J. C., Jones, D. R., Hall, S. D., Flockhart, D. A. and Desta, Z.: The Cytochrome P450 2B6 (CYP2B6) Is the Main Catalyst of Efavirenz Primary and Secondary Metabolism: Implication for HIV/ AIDS Therapy and Utility of Efavirenz as a Substrate Marker of CYP2B6 Catalytic Activity. J. Pharmacol. Exp. Ther., 306: 287-300 (2003).
11. Gatanaga, H., Hayashida, T., Tsuchiya, K., Yoshino, M., Kuwahara, T., Tsukada, H., Fujimoto, K., Sato, I., Ueda, M., Horiba, M., Hamaguchi, M., Yamamoto, M., Takata, N., Kimura, A., Koike, T., Gejyo, F., Matsushita, S., Shirasaka, T., Kimura, S. and Oka, S.: Successful Efavirenz Dose Reduction in HIV Type 1-Infected Individuals with Cytochrome P450 2B6 *6 and *26. Clin. Infect. Dis., 45: 1230-1237 (2007).
12. Manosuthi, W., Sukasem, C., Lueangniyomkul, A., Mankatitham, W., Thongyen, S., Nilkamhang, S., Manosuthi, S. and Sungkanuparph, S.: Impact of pharmacogenetic markers of CYP2B6 and clinical factors on plasma efavirenz level in HIV/tuberculosis co-infected Thai patients. J. Int. AIDS Soc., 15: 18410 (2012).
13. Yimer, G., Amogne, W., Habtewold, A., Makonnen, E., Ueda, N., Suda, A., Worku, A., Haefeli, W. E., Burhenne, J., Aderaye, G., Lindquist, L. and Aklillu, E.: High plasma efavirenz level and CYP2B6*6 are associated with efavirenz-based HAART-induced liver injury in the treatment of naïve HIV patients from Ethiopia: a prospective cohort study. Pharmacogenomics J., 12: 499-506 (2012).
14. Tsuchiya, K., Gatanaga, H., Tachikawa, N., Teruya, K., Kikuchi, Y., Yoshino, M., Kuwahara, T., Shirasaka, T., Kimura, S. and Oka, S.: Homozygous CYP2B6 *6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens. Biochem. Biophys. Res. Commun., 319: 1322-1326 (2004).
15. Rotger, M., Tegude, H., Colombo, S., Cavassini, M., Furrer, H., Décosterd, L., Blievernicht, J., Saussele, T., Günthard, H. F., Schwab, M., Eichelbaum, M., Telenti, A. and Zanger, U. M.: Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals. Clin. Pharmacol. Ther., 81: 557-566 (2007).
16. Carr, D. F., la Porte, C. J., Pirmohamed, M., Owen, A. and Cortes, C. P.: Haplotype structure of CYP2B6 and association with plasma efavirenz concentrations in a Chilean HIV cohort. J. Antimicrob. Chemother., 65: 1889-1893 (2010).
17. Lubomirov, R., Colombo, S., di Iulio, J., Ledergerber, B., Martinez, R., Cavassini, M., Hirschel, B., Bernasconi, E., Elzi, L., Vernazza, P., Furrer, H., Günthard, H. F. and Telenti, A.: Swiss HIV Cohort Study: Association of pharmacogenetic markers with premature discontinuation of first-line anti-HIV therapy: an observational cohort study. J. Infect. Dis., 203: 246-257 (2011).
18. Do, N. T., Phiri, K., Bussmann, H., Gaolathe, T., Marlink, R. G. and Wester, C. W.: Psychosocial factors affecting medication adherence among HIV-1 infected adults receiving combination antiretroviral therapy (cART) in Botswana. AIDS Res. Hum. Retroviruses, 26: 685-691 (2010).
19. Sukasem, C., Churdboonchart, V., Chasombat, S., Kohreanudom, S., Watitpun, C., Pasomsub, E., Piroj, W., Tiensuwan, M. and Chantratita, W.: Surveillance of genotypic resistance mutations in HIV-1 treated individuals after completion of the National Access to Antiretroviral Program in Thailand. Infection, 35: 81-88 (2007).
20. Sukasem, C., Churdboonchart, V., Chasombat, S., Kohreanudom, S., Watitpun, C., Piroj, W., Tiensuwan, M. and Chantratita, W.: Prevalence of antiretroviral drug resistance in treated HIV-1 infected patients: under the initiative of access to the NNRTI-based regimen in Thailand. J. Chemother., 19: 528-535 (2007).
21. Sukasem, C., Churdboonchart, V., Sirisidthi, K., Riengrojpitak, S., Chasombat, S., Watitpun, C., Piroj, W., Tiensuwan, M. and Chantratita, W.: Genotypic resistance mutations in treatment-naïve and treatmentexperienced patients under widespread use of antiretroviral drug in Thailand: Implication for further epidemiologic surveillance. Jpn. J. Infect. Dis., 60: 284-289 (2007).
22. Sukasem, C., Churdboonchart, V., Sukeepaisarncharoen, W., Piroj, W., Inwisai, T., Tiensuwan, M. and Chantratita, W.: Genotypic resistance profiles in antiretroviral-naive HIV-1 infections before and after initiation of first-line HAART: Impact of polymorphism on therapy resistance. Int. J. Antimicrob. Agents, 31: 277-281 (2008).
23. Sungkanuparph, S., Sukasem, C., Kiertiburanakul, S., Pasomsub, E. and Chantratita, W.: Emergence of HIV-1 drug resistance mutations among antiretroviral-naive HIV-1-infected patients after rapid scaling up of antiretroviral therapy in Thailand. J. Int. AIDS Soc., 15: 12 (2012).
24. Manosuthi, W., Butler, D. M., Chantratita, W., Sukasem, C., Richman, D. D. and Smith, D. M.: Patients infected with HIV-1 subtype CRF01_AE and failing first-line Nevirapine-and Efavirenz-based regimens demonstrate consideration cross resistance to Etravirine. AIDS Res. Hum. Retroviruses, 26: 609-611 (2010).
25. Kiertiburanakul, S., Wiboonchutikul, S., Sukasem, C., Chantratita, W. and Sungkanuparph, S.: Using of nevirapine is associated with intermediate and reduced response to etravirine among HIV-infected patients who experienced virologic failure in a resource-limited setting. J. Clin. Virol., 47: 330-334 (2010).
26. To, K. W., Liu, S. T., Cheung, S. W., Chan, D. P., Chan, R. C. and Lee, S. S.: Pharmacokinetics of plasma efavirenz and CYP2B6 polymorphism in southern Chinese. Ther. Drug Monit., 31: 527-530 (2009).
27. Manosuthi, W., Sungkanuparph, S., Tantanathip, P., Lueangniyomkul, A., Mankatitham, W., Prasithsirskul, W., Burapatarawong, S., Thongyen, S., Likanonsakul, S., Thawornwa, U., Prommool, V. and Ruxrungtham, K.: N2R Study Team. A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study. Clin. Infect. Dis., 48: 1752-1759 (2009).
28. Aurpibul, L., Chotirosniramit, N., Sugandhavesa, P., Kosachunhanun, N., Thetket, S., Supindham, T., Piyamongkol, W. and Supparatpinyo, K.: Correlation of CYP2B6-516G>T Polymorphism with Plasma Efavirenz Concentration and Depression in HIV-Infected Adults in Northern Thailand. Curr. HIV Res., 10: 653-660 (2012).
29. Jacob, R. M., Johnstone, E. C., Neville, M. J. and Walton, R. T.: Identification of CYP2B6 sequence variants by use of multiplex PCR with allele-specific genotyping. Clin. Chem., 50: 1372-1377 (2004).
30. Klein, K., Lang, T., Saussele, T., Barbosa-Sicard, E., Schunck, W. H., Eichelbaum, M., Schwab, M. and Zanger, U. M.: Genetic variability of CYP2B6 in populations of African and Asian origin: allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz. Pharmacogenet. Genomics, 15: 861-873 (2005).
31. Wang, J., Sönnerborg, A., Rane, A., Josephson, F., Lundgren, S., Ståhle, L. and Ingelman-Sundberg, M.: Identification of a novel specific CYP2B6 allele in Africans causing impaired metabolism of the HIV drug efavirenz. Pharmacogenet. Genomics, 16: 191-198 (2006).
32. Chen, J., Sun, J., Ma, Q., Yao, Y., Wang, Z., Zhang, L., Li, L., Sun, F. and Lu, H.: CYP2B6 polymorphism and nonnucleoside reverse transcriptase inhibitor plasma concentrations in Chinese HIV-infected patients. Ther. Drug Monit., 32: 573-578 (2010).
33. di Iulio, J., Fayet, A., Arab-Alameddine, M., Rotger, M., Lubomirov, R., Cavassini, M., Furrer, H., Günthard, H. F., Colombo, S., Csajka, C., Eap, C. B., Decosterd, L. A. and Telenti, A.: Swiss HIV Cohort Study: In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function. Pharmacogenet. Genomics, 19: 300-309 (2009).
34. Uttayamakul, S., Likanonsakul, S., Manosuthi, W., Wichukchinda, N., Kalambaheti, T., Nakayama, E. E., Shioda, T. and Khusmith, S.: Effects of CYP2B6 G516T polymorphisms on plasma efavirenz and nevirapine levels when co-administered with rifampicin in HIV/TB co-infected Thai adults. AIDS Res. Ther., 7: 8 (2010).
35. Kwara, A., Lartey, M., Sagoe, K. W., Rzek, N. L. and Court, M. H.: CYP2B6 (c.516G1/4T) and CYP2A6 (*9B and/or *17) polymorphisms are independent predictors of efavirenz plasma concentrations in HIVinfected patients. Br. J. Clin. Pharmacol., 67: 427-436 (2009).
36. Kwara, A., Larteym, M., Sagoe, K. W., Kenu, E. and Court, M. H.: CYP2B6, CYP2A6 and UGT2B7 genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patients. AIDS, 23: 2101-2106 (2009).
37. Clevenbergh, P., Mouly, S., Sellier, P., Badsi, E., Cervoni, J., Vincent, V., Trout, H. and Bergmann, J. F.: Improving HIV infection management using antiretroviral plasma drug levels monitoring: a clinician's point of view. Curr. HIV Res., 2: 309-321 (2004).
38. Fabbiani, M., Bracciale, L., Ragazzoni, E., Santangelo, R., Cattani, P., Di Giambenedetto, S., Fadda, G., Navarra, P., Cauda, R. and De Luca, A.: Relationship between antiretroviral plasma concentration and emergence of HIV-1 resistance mutations at treatment failure. Infection, 39: 563-569 (2011).
39. Pretorius, E., Klinker, H. and Rosenkranz, B.: The role of therapeutic drug monitoring in the management of patients with human immunodeficiency virus infection. Ther. Drug Monit., 33: 265-274 (2011).